The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient
After five years of painstaking lab work, more than 350,000 hours of genome sequencing and £200 million ($253 million) in investment, UK Biobank has completed and released
US biotech Moderna has completed the installation of its clinical laboratories at its new R&D facility in the UK dedicated to the discovery of new mRNA vaccines and th
A retrospective analysis of the clinical data supporting 20 FDA-approved prescription digital therapeutics has found that they often fail to apply rigorous standards of ev
Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Thera
Gene-editing company Beam Therapeutics has shifted into reverse, slashing staff and R&D programmes after a period of expansion since its public debut in 2020.
Japan’s Taisho Pharmaceutical looks like it could be heading into private ownership, thanks to a management buyout offer (MBO) that could value the company at almost $5 bi
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio